Anidulafungin/voriconazole

Drug Profile

Anidulafungin/voriconazole

Alternative Names: Eraxis Vfend combination; Voriconazole/anidulafungin

Latest Information Update: 12 Nov 2012

Price : $50

At a glance

  • Originator Pfizer
  • Class Antifungals; Cyclic peptides; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Aspergillosis

Most Recent Events

  • 09 Aug 2012 Discontinued - Phase-III for Aspergillosis in Canada (IV/PO combination)
  • 09 Aug 2012 Discontinued - Phase-III for Aspergillosis in South America (IV/PO combination)
  • 09 Aug 2012 Discontinued - Phase-III for Aspergillosis in Australia (IV/PO combination)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top